News Column

New Biochemistry Findings from University of Alberta Discussed (Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions)

September 10, 2014



By a News Reporter-Staff News Editor at Biotech Week -- New research on Biochemistry is the subject of a report. According to news reporting from Edmonton, Canada, by NewsRx journalists, research stated, "Autotaxin is a secreted enzyme that produces most of the extracellular lysophosphatidate from lysophosphatidylcholine, the most abundant phospholipid in blood plasma. Lysophosphatidate mediates many physiological and pathological processes by signaling through at least six G-protein coupled receptors to promote cell survival, proliferation and migration."

The news correspondents obtained a quote from the research from the University of Alberta, "The autotaxin/lysophosphatidate signaling axis is involved in wound healing and tissue remodeling, and it drives many chronic inflammatory conditions from fibrosis to colitis, asthma and cancer. In cancer, lysophosphatidate signaling promotes resistance to chemotherapy and radiotherapy, and increases both angiogenesis and metastasis. Research into autotaxin inhibitors is accelerating, both as primary and adjuvant therapy. Historically, autotaxin inhibitors had poor bioavailability profiles and thus had limited efficacy in vivo. This situation is now changing, especially since the recent crystal structure of autotaxin is now enabling rational inhibitor design. In this review, we will summarize current knowledge on autotaxin-mediated disease processes including cancer, and discuss recent advancements in the development of autotaxin-targeting strategies."

According to the news reporters, the research concluded: "We will also provide new insights into autotaxin as an inflammatory mediator in the tumor microenvironment that promotes cancer progression and therapy resistance."

For more information on this research see: Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions. FEBS Letters, 2014;588(16):2712-2727. FEBS Letters can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; FEBS Letters - www.elsevier.com/wps/product/cws_home/506085)

Our news journalists report that additional information may be obtained by contacting M.G.K. Benesch, University of Alberta, Dept. of Surg, Edmonton, AB T6G 2R7, Canada. Additional authors for this research include Y.M. Ko, T.P.W. McMullen and D.N. Brindley (see also Biochemistry).

Keywords for this news article include: Edmonton, Alberta, Canada, North and Central America, Biochemistry, Cancer, Oncology

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters